Hendrik Scholl

Person

Last mentioned: Mar 11, 2026

Timeline

Dec 31, 2026
Commercialization Ramp-up

Planned $200M-$250M expenditure for market entry and launch preparation.
Jun 30, 2026
Target NDA Submission

Company plans to submit New Drug Application to the FDA by the end of Q2 2026.
Mar 10, 2026
Phase 3 Data Release

Belite Bio details 36% lesion growth reduction at Leerink conference.

Stories mentioning Hendrik Scholl 1

Belite Bio's Tinlarebant Slows Stargardt Lesion Growth by 36% in Phase 3

Belite Bio (BLTE) has reported positive Phase 3 DRAGON trial results for its lead candidate, Tinlarebant, demonstrating a 36% reduction in lesion growth for Stargardt disease. The oral therapy is now positioned for a Q2 2026 NDA submission as the company prepares for a $200M-$250M commercial launch.

Mar 11, 2026 2 sources